| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Theravance Biopharma Inc (NASDAQ: TBPH)
TBPH Technical Analysis
3
| As on 9th Jun 2023 TBPH STOCK Price closed @ 11.02 and we RECOMMEND Buy for LONG-TERM with Stoploss of 9.64 & Buy for SHORT-TERM with Stoploss of 9.99 we also expect STOCK to react on Following IMPORTANT LEVELS. |
TBPHSTOCK Price
| Open | 11.10 | Change | Price | % |
| High | 11.10 | 1 Day | -0.13 | -1.17 |
| Low | 10.94 | 1 Week | -0.04 | -0.36 |
| Close | 11.02 | 1 Month | -0.17 | -1.52 |
| Volume | 350700 | 1 Year | 0.27 | 2.51 |
| 52 Week High 12.96 | 52 Week Low 8.33 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| TBPH Daily Charts |
TBPH Intraday Charts |
Whats New @ Bazaartrend |
TBPH Free Analysis |
|
|
TBPH Important Levels Intraday
| RESISTANCE | 11.33 |
| RESISTANCE | 11.23 |
| RESISTANCE | 11.17 |
| RESISTANCE | 11.11 |
| SUPPORT | 10.93 |
| SUPPORT | 10.87 |
| SUPPORT | 10.81 |
| SUPPORT | 10.71 |
TBPH Forecast May 2024
| 4th UP Forecast | 21.54 |
| 3rd UP Forecast | 18.17 |
| 2nd UP Forecast | 16.08 |
| 1st UP Forecast | 14 |
| 1st DOWN Forecast | 8.04 |
| 2nd DOWN Forecast | 5.96 |
| 3rd DOWN Forecast | 3.87 |
| 4th DOWN Forecast | 0.5 |
TBPH Weekly Forecast
| 4th UP Forecast | 12.74 |
| 3rd UP Forecast | 12.19 |
| 2nd UP Forecast | 11.85 |
| 1st UP Forecast | 11.51 |
| 1st DOWN Forecast | 10.53 |
| 2nd DOWN Forecast | 10.19 |
| 3rd DOWN Forecast | 9.85 |
| 4th DOWN Forecast | 9.30 |
TBPH Forecast2024
| 4th UP Forecast | 21.89 |
| 3rd UP Forecast | 18.4 |
| 2nd UP Forecast | 16.25 |
| 1st UP Forecast | 14.09 |
| 1st DOWN Forecast | 7.95 |
| 2nd DOWN Forecast | 5.79 |
| 3rd DOWN Forecast | 3.64 |
| 4th DOWN Forecast | 0.15 |
Theravance Biopharma Inc ( NASDAQ USA Symbol : TBPH )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
TBPH Business Profile
Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor that is in Phase IIb/III clinical trials for the treatment of rheumatoid arthritis, myelofibrosis, and ulcerative colitis, as well as for a range of inflammatory intestinal diseases, including ulcerative colitis and Crohn's disease. In addition, the company's product portfolio also comprise Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; TD-8236, an investigational, inhaled lung-selective pan-JAK inhibitor, which is Phase II clinical study for treatment of a range of inflammatory diseases; and TD-5202, an investigational, orally administered, gut-selective, irreversible JAK3 inhibitor that is in Phase I clinical study for treatment of inflammatory intestinal diseases. Further, it offers TRELEGY for the treatment of COPD; Velusetrag, an oral and investigational medicine for gastrointestinal motility disorders; and Selective 5-HT4 Agonist for treatment of gastrointestinal motility disorders. It has a licensing and collaboration agreements with Pfizer Inc., Viatris Inc., Janssen Biotech, Inc., Alfasigma S.p.A, and Takeda Pharmaceutical Company Limited. The company was incorporated in 2013 and is based in George Town, the Cayman Islands. Address: Ugland House, George Town, Cayman Islands, KY1-1104
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service